How Maryland Smith Is Helping the FDA Think About Drug Manufacturing and Risk
Pandemic-era disruptions underscored a troubling reality in the pharmaceutical industry – an outsized reliance on foreign manufacturers for the raw ingredients for drugs sold in the United States.
It’s a situation that exposes Americans to numerous risks – operational, financial, geopolitical and environmental. As concerns mount about those risks, the Food and Drug Administration’s Center for Drug Evaluation and Research (CDER), Office of Pharmaceutical Quality (OPQ) is looking to the University of Maryland’s Robert H. Smith School of Business for help with answers.